Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, Journal of Hepatology, vol.60, issue.6, pp.1268-1289, 2014. ,
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study, Hepatology, vol.63, issue.3, pp.827-838, 2016. ,
Risk factors for intrahepatic cholangiocarcinoma: A case-control study in China, World Journal of Gastroenterology, vol.14, issue.4, p.632, 2008. ,
Aspirin use and the risk of cholangiocarcinoma, Hepatology, vol.64, issue.3, pp.785-796, 2016. ,
Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control Study, Clinical Gastroenterology and Hepatology, vol.5, issue.10, pp.1221-1228, 2007. ,
Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control Study, PLoS ONE, vol.8, issue.7, p.e69981, 2013. ,
Prospective association of liver function biomarkers with development of hepatobiliary cancers, Cancer Epidemiology, vol.40, pp.179-187, 2016. ,
The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study, Journal of Surgical Oncology, vol.113, issue.7, pp.779-783, 2016. ,
Prevalence of Nonalcoholic Steatohepatitis Among Patients with Resectable Intrahepatic Cholangiocarcinoma, Journal of Gastrointestinal Surgery, vol.17, issue.4, pp.748-755, 2013. ,
Tumours of the liver and intrahepatic bile ducts, WHO Classification of Tumours, vol.1, pp.215-264, 2019. ,
Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome, World Journal of Surgery, vol.43, issue.8, pp.2048-2060, 2019. ,
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances, Hepatology, vol.69, issue.4, pp.1803-1815, 2019. ,
, European Association for the Study of the Liver (EASL), Liver, vol.21, issue.1, p.71, 2001.
, EASD, Diabetologia, vol.45, issue.6, pp.R25-R30, 2002.
, EASL?EASD?EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Journal of Hepatology, vol.64, issue.6, pp.1388-1402, 2016.
Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis, BMC Gastroenterology, vol.17, issue.1, p.149, 2017. ,
A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease, International Journal of Molecular Sciences, vol.18, issue.6, p.1134, 2017. ,
Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease, BMC Gastroenterology, vol.12, issue.1, 2012. ,
Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?, Liver International, vol.31, issue.3, pp.377-385, 2010. ,
Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators, Nature Reviews Gastroenterology & Hepatology, vol.16, issue.3, pp.160-174, 2018. ,
Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease, Hepatology, vol.69, issue.1, pp.107-120, 2018. ,
Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer, Cell, vol.175, issue.3, pp.679-694.e22, 2018. ,
Microbiota, NASH, HCC and the potential role of probiotics, Carcinogenesis, vol.38, issue.3, pp.231-240, 2017. ,
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, Journal of Hepatology, vol.61, issue.1, pp.75-81, 2014. ,
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period, Alimentary Pharmacology & Therapeutics, vol.46, issue.9, pp.856-863, 2017. ,
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases, Alimentary Pharmacology & Therapeutics, vol.48, issue.7, pp.696-703, 2018. ,
Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma, European Journal of Gastroenterology & Hepatology, vol.30, issue.5, pp.552-556, 2018. ,
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019, Digestive and Liver Disease, vol.51, issue.8, pp.1067-1073, 2019. ,
Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment, Journal of Gastrointestinal Surgery, vol.15, issue.4, pp.608-613, 2011. ,
Survival Outcomes and Prognostic Factors of Surgical Therapy for All Potentially Resectable Intrahepatic Cholangiocarcinoma: a Large Single-Center Cohort Study, Journal of Gastrointestinal Surgery, vol.18, issue.3, pp.562-572, 2014. ,
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ?personalized? approach to cancer staging, CA: A Cancer Journal for Clinicians, vol.67, issue.2, pp.93-99, 2017. ,
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, vol.60, issue.2, pp.565-575, 2014. ,
Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.41, issue.6, pp.1313-1321, 2005. ,
Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, vol.54, issue.1, pp.344-353, 2011. ,
Sensitivity Analysis Without Assumptions, Epidemiology, vol.27, issue.3, pp.368-377, 2016. ,
Sensitivity Analysis in Observational Research: Introducing the E-Value, Annals of Internal Medicine, vol.167, issue.4, p.268, 2017. ,